AmericasENPublic regulatory overview
Chile
Market Overview Population: Approximately 19.5 million (2024), one of South America's highest percapita income countries Healthcare system: Dualtrack structure — the public FONASA...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRModerate benefitCE evidence provides a strong technical-file template but does not replace the local review.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Chile
- Product line: Medical devices
- Regulator / source: Market characteristics: The medical device market is valued at approximately USD 1–1.5 billion per year, with an extremely high import dependency (approximately 95%). Per-capita healthcare expenditure is among the highest in Latin America. The regulatory environment is relatively efficient, making Chile one of the most commercially favorable regulatory environments in the region. Chile has signed free trade agreements (FTAs) with numerous countries, resulting in high trade openness
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Market characteristics: The medical device market is valued at approximately USD 1–1.5 billion per year, with an extremely high import dependency (approximately 95%). Per-capita healthcare expenditure is among the highest in Latin America. The regulatory environment is relatively efficient, making Chile one of the most commercially favorable regulatory environments in the region. Chile has signed free trade agreements (FTAs) with numerous countries, resulting in high trade openness
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 19.5 million (2024), one of South America's highest per-capita income countries
- Healthcare system: Dual-track structure — the public FONASA (Fondo Nacional de Salud, covering approximately 80% of the population) and the private ISAPRE system (Instituciones de Salud Previsional, covering higher-income groups at approximately 15–20%); the public hospital network is managed by MINSAL (Ministerio de Salud)
- Market characteristics: The medical device market is valued at approximately USD 1–1.5 billion per year, with an extremely high import dependency (approximately 95%). Per-capita healthcare expenditure is among the highest in Latin America. The regulatory environment is relatively efficient, making Chile one of the most commercially favorable regulatory environments in the region. Chile has signed free trade agreements (FTAs) with numerous countries, resulting in high trade openness
- Regulatory maturity: Moderate to high — the ISP/ANAMED regulatory framework is based on the EU GHTF framework; technical requirements are clearly defined. Reviewers are professionally competent, and administrative efficiency is among the best in Latin America. The overall business environment is sound and corruption risk is low
Regulatory Authority
- Primary authority: ISP (Instituto de Salud Pública de Chile); the ANAMED division (Agencia Nacional de Medicamentos) is responsible for substantive review
- Official portal: https://www.ispch.cl; electronic filing: https://www.ispch.cl/registros-autorizaciones
- Key regulations:
- DFL 725/1968 (Health Code, Código Sanitario)
- DS 825/1998 (medical device registration regulations)
- Resolución Exenta 887/2019 (classification and registration update guidelines)
- Circular 1/2013 (technical documentation guidance)
- Ley 20.850/2015 (Ricarte Soto Law, coverage of high-value innovative technologies)
- Product-specific Circulares Técnicas (technical circulars)
Device Classification
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Clase A | Very low risk | EU Class I (exempt) / FDA Class I (exempt) | Simplest process; some products exempt from registration |
| Clase B | Low-moderate risk | EU Class I-IIa / FDA Class I-II | Standard registration; relatively fast |
| Clase C | Moderate-high risk | EU Class IIb / FDA Class II-III | More complete technical documentation required |
| Clase D | High risk | EU Class III / FDA Class III | Most stringent review; complete clinical evidence required |
Note: Classification is based on DS 825/1998 and subsequent update notices. ISP/ANAMED accepts manufacturer self-classification, confirmed at the time of submission. A formal classification inquiry may be submitted through official channels.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.